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INTRODUCTION
Synovial sarcoma (SS) is an aggressive soft-tissue tumor 
with a tendency to recur locally and high potential for distant 
metastasis. Morphologically, these tumors consist of spin-
dle-like cells positive by immunohistochemical staining for 
epithelial markers. SS constitutes 5-10% of all soft-tissue sarco-
mas and typically affects adolescents and young adults [1-4]. 
This sarcoma is most often found in the lower extremities 
(especially the knee), upper extremities, and the head and 
neck (mostly in the parapharyngeal region). SS can be classi-
fied into three histological types: monophasic (pure epithelioid 
or fibroblastic cells), biphasic, and poorly differentiated [1-5], 
and is diagnosed upon histopathological findings of epithelial 
differentiation or immunostaining for cytokeratin or epithe-
lial membrane antigen (EMA). While some investigators have 
reported transducer-like enhancer of split 1 (TLE1) to be an 
extremely sensitive biomarker for SS [1,2,6], others showed 
a low specificity of TLE1 in diagnosing SS [7]. Recently, the 
t(X;18) (SYT-SSX) translocation has been recommended as 
the most reliable diagnostic tool [1,2,8].
The prognosis for SS is usually poor, with 5- and 10-year 
survival rates between 36-76% and 20-63%, respectively [3,9-11]. 
Factors associated with a better prognosis include age 
<20 years, tumor size smaller than 5 cm, more distal location 
along the extremities, lower tumor stage, and appropriate 
excision. Predictors of poor prognosis include less-differenti-
ated tumor areas, presence of necrosis, and high mitotic activ-
ity, i.e., >10 mitoses/10 high power fields (HPFs) [3,5,9,12].
Enhancer of zeste homologue 2 (EZH2) belongs to the 
polycomb group (PcG) proteins of cell cycle regulators that 
suppress transcription. An excessive expression of EZH2 is 
found in various carcinomas, lymphomas, and soft tissue 
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ABSTRACT
Synovial sarcoma (SS) is a type of soft-tissue sarcoma, often linked to poor survival. Although overexpression of enhancer of zeste homologue 
2 (EZH2) has been associated with poor prognosis in different tumors, a few studies investigated this link in SS. Here, we analyzed the rela-
tionship between EZH2 expression and prognostic factors in SS. We included 29 patients with SS. Immunostaining of EZH2 was performed 
with (D2C9) XPTM Rabbit mAb antibody, and the results were classified as low EZH2 expression (negative or weak expression) and high EZH2 
expression category (moderate or strong expression). Analysis of survival in relation to prognostic factors was performed with Kaplan-Meier 
survival curves and Cox proportional hazard regression analysis. Our sample included 19/29 female and 10/29 male patients, with age range 
16-63 years. The tumor diameter ranged from 2 to 15 cm. Necrosis was observed in 15/29 cases. Sixteen cases had >10 mitoses per 50 high-power 
fields (HPFs). Out of 29 cases, 14 showed low and 15 had high EZH2 expression. Statistically significant results were obtained for the association 
between the presence of metastasis and necrosis (p = 0.042), high EZH2 expression and distant metastasis (p = 0.018), high EZH2 expression 
and necrosis (p = 0.016), and high EZH2 expression and the tumor size >5 cm versus tumor size ≤5 cm (p = 0.014). Patients with all of the follow-
ing: the tumor size ≤5 cm, low EZH2 expression, and without necrosis and distant metastasis had significantly longer survival time. Our results 
are consistent with previous studies, suggesting that EZH2 overexpression is an indicator of poor prognosis in SS.
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sarcomas, and growing evidence suggests that this overex-
pression correlates with the aggressiveness and poor clinical 
outcome of such tumors [13-22]. However, few studies have 
investigated the expression of EZH2 in SS [23-25]. The aim 
of this study was to investigate the relationship between the 
EZH2 expression as evaluated by immunohistochemistry and 
known prognostic indicators in SS.
MATERIALS AND METHODS
We retrospectively analyzed the data for 29 patients diag-
nosed with SS between 2002 and 2014 at our pathology depart-
ment. All slides were reviewed and re-evaluated. The following 
information was collected from the medical records: age, gen-
der, tumor site, tumor size, tumor grade, follow-up duration, 
recurrence, metastasis, and survival time. We used the World 
Health Organization (WHO) guidelines for the histological 
type and Fédération Nationale des Centers de Lutte Contre le 
Cancer (FNCLCC) criteria to determine the tumor grade (dif-
ferentiation, mitotic index, and necrosis). Tumors were clas-
sified histologically into three groups: biphasic, monophasic 
fibrous, or poorly differentiated. The study was conducted in 
accordance with the Institutional Ethical Guidelines.
Immunohistochemical study
Four-micron-thick serial sections were obtained 
from formalin-fixed, paraffin-embedded (FFPE) blocks. 
Immunohistochemical staining was performed on a Leica 
BOND-MAX Autostainer (Leica Microsystems, Berlin, 
Germany), and peroxidase/DAB Bond Polymer Refine 
Detection System (Leica Microsystems) was used for visu-
alization. EZH2 immunohistostaining was done with 
D2C9XPTM Rabbit mAb (1:100 dilution) primary antibodies, 
while other sections were reserved for hematoxylin and eosin 
(H&E) staining.
Scoring system
To assess the immunohistochemical labeling of EZH2, the 
immunostained slides were evaluated using a 10× magnifica-
tion. The nuclear staining was scored as follows: a) negative, 
no visible staining, b) weak, 1-25% of nuclei were positive, c) 
moderate, 25-75%, and d) strong, over 75% [19]. The EZH2 
staining was classified into two categories according to the 
nuclear staining: a “low EZH2 expression category” with neg-
ative or weak expression, and a “high EZH2 expression cate-
gory” with moderate or strong expression.
Statistical analysis
The association between EZH2 expression and the pres-
ence of distant metastasis was tested by the Fisher’s exact 
test and Fisher-Freeman-Halton test where appropriate. The 
log-rank test was used to determine the difference between 
the Kaplan-Meier curves for survival time. Median survival 
time was reported. To determine the prognostic factors that 
affect the overall survival time, we performed the Cox pro-
portional hazard regression analysis with backward selec-
tion procedure following the Kaplan-Meier analysis. The 
significant predictors obtained in the Kaplan-Meier analysis 
were entered into the Cox proportional hazard regression, 
and the results of the final step were reported. The results 
were reported as hazard ratios with 95% confidence intervals 
(CIs) and the related p-values. All analyses were performed 
using IBM SPSS Statistics for Windows, Version 21.0. (IBM 
Corp., Armonk, NY). A value of p < 0.05 was considered as 
statistically significant.
RESULTS
Clinical data
The study included 19/29 female (65.5%), and 10/29 male 
(34.5%) patients with age range 16-63 (mean age: 35). The mean 
diameter of the tumors was 8  cm, ranging from 2 to 15  cm. 
Eight tumors measured ≤5  cm, 21 tumors were >5  cm. The 
tumors occurred in the periphery in 22/29  cases (76%) and 
centrally in 7/29 cases (24%).
The specimens consisted of 15 marginal excisions and 14 
wide resections. In 4 cases, recurrence was treated by amputa-
tion, including two hemipelvectomies and two finger amputa-
tions. Twenty-two patients were treated with both chemo and 
radiation therapy following the surgery.
The follow-up information for a minimum of 13 months 
was available for all 29 cases (13-147 months range). Out of the 
29 cases, 15 (52%) patients died of the tumor, 9 (31%) had local 
recurrence, and 5 (17.2%) had distant metastasis.
Pathological features
Histopathologically, 14/29 cases were monophasic (48.3%), 
11/29 biphasic (37.9%), and 4/29 poorly differentiated (13.8%) 
(Figure 1 and 2). In 1 case, there were large areas of epithelial 
differentiation, and 3  cases localized on the periphery had 
large areas of calcification.
Out of the 29 cases, 14 (48.3%) were evaluated as Grade II 
and 15 (51.7%) as Grade III. We observed necrosis in 15 (51.7%) 
cases, the mitotic rate per 50 HPFs ranged from 4 to 39. In 
addition, 16 cases had >10 mitoses per 50 HPFs.
We examined the effects of clinicopathological parameters 
on distant metastasis, and found that there was a statistically 
significant association between metastases and the presence 
of necrosis (p = 0.042). Other clinicopathological parameters 
of the tumor (i.e.,  age, gender, tumor location, tumor size, 
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histological type, grade, and mitoses) did not show significant 
association with distant metastasis (Table 1).
Immunohistochemical findings and the 
relationship with clinicopathological features
Out of the 29 patients, 14 (48.3%) cases were classified as 
low EZH2 expression and 15  (51.7%) were classified as high 
EZH2 expression. The relationship between the EZH2 expres-
sion and clinicopathological features in SS patients is summa-
rized in Table 2 and Figure 1 and 2.
There were statistically significant correlations between 
high EZH2 expression and distant metastasis (p = 0.018) and 
the presence of necrosis (p = 0.016).
In addition, high EZH2 expression was significantly more 
frequently detected in patients with the tumor size >5  cm 
compared with the tumor size ≤5 cm (p = 0.014). Patients with 
low EZH2 expression were predominantly female (p = 0.050).
On the other hand, no statistically significant relationship 
was observed between EZH2 expression and other clinico-
pathological factors, including age, tumor location, size, local 
recurrence, histological type, grade, and mitoses.
Survival analysis
Using the Kaplan-Meier analysis, the overall median fol-
low-up for the entire study population was 68 months (95%, 
CI: 15.1-34.9 months). The survival was not affected by the age, 
TABLE 1. Clinicopathological features of patients with distant 
metastasis compared with patients without distant metastasis
Clinicopathological features
Distant metastasis
p valueWith 
n=5 (%)
Without 
n =24 (%)
Age
<19 0 5 (20.80) 0.659
20-34 2 (40) 5 (20.80)
>35 3 (60) 14 (58.30)
Sex (male/female) 3/2 7/17 0.306
Tumor location
Periphery 4 (80) 18 (75) 1.00
Centrally 1 (20) 6 (25)
Tumor size
≤5 cm 0 8 (33.30) 0.283
>5 cm 5 (100) 16 (66.70)
Histological type
Monophasic 2 (40) 12 (50) 1.00
Biphasic 2 (40) 9 (37.50)
Poorly differentiated 1 (20) 3 (12.50)
Grade
Grade 2 3 (60) 11 (45.80) 0.651
Grade 3 2 (40) 13 (54.20)
Mitosis
≤10 1 (20) 12 (50) 0.343
>10 4 (80) 12 (50)
Necrosis (presence) 5 (100) 10 (41.70) 0.042
Chemo and radiation therapy 5 (100) 17 (70.80) 0.296
TABLE 2. Demographic and clinicopathological characteristics of 
patients with respect to EZH2 expression
Demographic and 
clinicopathological 
characteristics
EZH2 expression
p valueLow n=14 
(%) High n=15 (%)
Age
<19 2 (14.30) 3 (20) 0.462
20-34 2 (14.30) 5 (33.30)
>35 10 (71.40) 7 (46.70)
Sex (male/female) 2/12 8/7 0.050
Tumor location
Periphery 9 (64.30) 13 (86.70) 0.215
Centrally 5 (35.70) 2 (13.30)
Tumor size
≤5 cm 7 (50) 1 (6.70) 0.014
>5 cm 7 (50) 14 (93.30)
Histological type
Monophasic 8 (57.10) 6 (40) 0.612
Biphasic 5 (35.70) 6 (40)
Poorly differentiated 1 (7.10) 3 (20)
Grade
Grade 2 9 (64.30) 5 (33.30) 0.096
Grade 3 5 (35.70) 10 (66.70)
Mitosis
≤10 9 (64.30) 4 (26.70) 0.066
>10 5 (35.70) 11 (73.30)
Necrosis (presence) 4 (28.60) 11 (73.30) 0.016
Local recurrence 
(presence) 3 (21.40) 6 (40) 0.427
Distant metastasis 
(presence) 0 5 (33.30) 0.018
EZH2: Enhancer of zeste homologue 2
gender, tumor location, local recurrence, histological type, 
grade, mitoses, chemo and radiation therapy, and type of sur-
gery (Table 3). However, patients with the tumor size ≤5 cm, 
without necrosis, without distant metastasis and low EZH2 
expression had a significantly longer survival time (p = 0.022, 
p = 0.006, p = 0.001, and p = 0.017, respectively; Table  3). 
Moreover, the analysis of independent risk factors affecting 
survival showed that patients with distant metastasis had a 
3.59 risk factor for the total survival time.
DISCUSSION
EZH2 is a PcG protein. This family consists of transcrip-
tional suppressor regulators responsible for the repair of DNA 
damage, cellular differentiation, cellular aging, and apoptosis. 
PcG proteins are involved in the maintenance of stem cell 
character and in the tumor development. Specifically, EZH2 
acts as a histone methyltransferase targeting the N-terminal 
tail of histone H3 to produce a characteristic H3-Lys27 
trimethylation (H3K27me3) pattern. EZH2 is expressed at 
high levels in cells exhibiting an embryonic gene expression 
pattern, and its expression declines with tissue maturation and 
differentiation. Recent studies have suggested that EZH2 over-
expression might be related to aggressive behavior and poor 
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prognosis in various carcinomas, lymphomas, and soft tissue 
sarcomas [13-25].
Different clinical and pathological factors have been sug-
gested as indicators of SS prognosis. Recent studies including 
a large number of cases with long follow-up periods have 
shown that the advanced stage, high grade, male gender, age 
>40  years, tumor >5  cm in diameter, poor differentiation, as 
well as occurrence at the proximal sites along the extremities 
FIGURE 1. Enhancer of zeste homologue 2 (EZH2) expression in two histological types of synovial sarcoma (SS). (A) Monophasic fibrous 
SS consisting of relatively homogeneous spindle cells arranged in a fascicular pattern (H&E, ×100), (B) EZH2 immunostaining is strong in 
the same tumor (×200), (C) biphasic SS, (H&E, ×100), and (D) EZH2 immunostaining shows a moderate expression of EZH2 in the glan-
dular epithelium (×100).
B
D
A
C
FIGURE 2. (A) Poorly differentiated synovial sarcoma (SS) with a prominent hemangiopericytoma-like vascular pattern (H&E, ×200), (B) 
in the same tumor, enhancer of zeste homologue 2 (EZH2) immunostaining is weak (×200), (C) monophasic fibrous SS with extensive 
tumor calcification (H&E, ×100), and (D) in the same tumor, EZH2 immunostaining is negative (×100).
B
D
A
C
Ulviye Yalçınkaya, et al.: EZH2 expression in synovial sarcomas
306
are associated with poor prognosis [4,5,9,26-28]. On the other 
hand, younger age (adolescence), small size, distal location, 
calcification, and thorough resection are indicators of good 
prognosis [3,9,29].
SS is aggressive, with a 50-70% tendency to recur locally 
or to metastasize to the lungs, bones, and sometimes to the 
lymph nodes [3,4,9]. In this study, we found that patients with 
the tumor size ≤5 cm (p = 0.022) and without distant metasta-
sis (p = 0.001) had better survival. We also demonstrated that 
the patients with distant metastasis had a 3.59 risk factor for the 
total survival time. Although the t(X;18) translocation involv-
ing the SSX2 gene has been correlated with better outcomes, 
no studies have confirmed that it is an independent prognostic 
factor for SS [3,27,28]. Moreover, necrosis, vascular invasion, 
high mitotic activity, and high Ki-67 proliferative index are 
accepted histopathological predictors of the shortened sur-
vival [9,13,27]. Our results showed that the patients without 
necrosis had a significantly higher survival time (p = 0.006).
In the last decade, several new immunohistochemical 
and molecular markers were investigated as indicators of 
SS prognosis and potential therapeutic targets [9]. To this 
end, we aimed to evaluate whether immunohistochemical 
EZH2 expression correlates with known prognostic indi-
cators of SS.
A histological type may serve as a prognostic indicator 
for SS. Tumors with >20% of poorly differentiated histology 
show more aggressive behavior [5,8,9]. Similarly, Paulino [30] 
reported that biphasic histology is associated with a better 
clinical outcome more frequently than the monophasic his-
tology; in addition, Krieg et al. [3] found that a histological 
TABLE 3. Median survival time in months according to the Kaplan-Meier analysis in relation to demographic and clinicopathological 
characteristics
Risk factor Number of patients at risk (%) Number of events (%) Duration of survival in months p value
Age
<19 5 (17.20) 3 (60) 37 0.982
20-34 7 (24.10) 4 (57.10) 40
>35 17 (58.60) 7 (41.20) 68
Sex
Male 10 (34.50) 7 (70) 60 0.192
Female 19 (65.50) 7 (36.80) 147
Tumor location
Periphery 22 (75.90) 11 (50) 68 0.386
Centrally 7 (24.10) 3 (42.90) 24
Tumor size
≤5 cm 8 (27.60) 1 (12.50) 81.17 0.022
>5 cm 21 (72.40) 13 (61.90) 66.04
Histological type
Monophasic 14 (48.30) 7 (50) 40 0.998
Biphasic 11 (37.90) 5 (45.50) 21.33
Poorly differentiated 4 (13.80) 2 (50) 68
Grade
Grade 2 14 (48.30) 6 (42.90) 147 0.135
Grade 3 15 (51.70) 8 (53.30) 60
Mitosis
≤10 13 (44.80) 6 (46.20) 130 0.183
>10 16 (55.20) 8 (50) 60
Necrosis
Presence (n=15) 15 (51.70) 10 (66.70) 26 0.006
Absence (n=14) 14 (48.30) 4 (28.60) 130
Local recurrence 
Presence 9 (31) 6 (66.70) 60 0.174
Absence 20 (69) 8 (40) 130
Distant metastasis
Presence 5 (17.20) 5 (100) 20 0.001
Absence 24 (82.80) 9 (37.50) 130
EZH2 expression
Low 14 (48.30) 2 (14.30) 82.75 0.017
High 15 (51.70) 12 (80) 60.01
Chemo and radiation therapy
Yes 22 (75.90) 10 (45.50) 147 0.511
No 7 (24.10) 4 (57.10) 60
EZH2: Enhancer of zeste homologue 2
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subtype can also serve as an independent prognostic factor 
for SS [3,30]. Changchien et al. [23] observed higher EZH2 
expression in poorly differentiated SS and suggested that 
EZH2 expression might correlate with aggressive clinical 
behavior [23]. We found high EZH2 expression in 3 out of 
4 cases of poorly differentiated SS, but there was no statisti-
cally significant relationship between EZH2 expression and 
the histological subtype.
Although some studies suggest that gender does not cor-
relate with prognosis in SS, other authors report that male 
gender is associated with a worse prognosis [3,31,32]. In this 
study, patients with low EZH2 expression were predomi-
nantly female (p = 0.050), which is consistent with the previ-
ous studies.
Similar to other soft tissue sarcomas, SS tends to have a 
better prognosis in younger patients [12,26,30,31]. A  study 
from a single institution on 271 cases of SS found a significant 
correlation between advanced age and poor prognosis [26]. 
Similarly, another study on 121 SS cases reported that the age 
over 25 years was correlated with the lower disease-free sur-
vival [9]. Furthermore, SS located in the extremities is reported 
to have a better prognosis than the tumor in the head-neck 
region [3,30,33,34]. For example, in children and adolescents 
SS in the extremities had a better prognosis than the tumors 
in other locations, and it was suggested that the treatment 
should be planned accordingly [34,35]. In our study, no signif-
icant relationship was observed between the age, tumor loca-
tion, and EZH2 expression.
The standard treatment for SS is wide resection of the 
tumor and surrounding tissue. SS recurs in 70-83% of cases 
with inadequate marginal resection. Recurrence may increase 
the risk of metastasis, and thus negatively influence the prog-
nosis. Aggressive surgery accompanied by chemo or radia-
tion therapy increases disease-free survival [3,4,26,33-35]. We 
found no statistically significant relationship between EZH2 
expression and treatment modality and local recurrence, 
and we demonstrated a significant correlation between high 
EZH2 expression and distant metastasis (p = 0.018).
In most studies of carcinoma, lymphoma, and soft-tissue 
sarcomas, EZH2 overexpression was an indicator of poor 
prognosis [13-15,19-25]. Similarly, we observed that low EZH2 
expression was associated with prolonged survival (p = 0.017).
Generally accepted indicators of prognosis in SS include 
tumor stage at presentation, tumor size, and FNCLCC tumor 
grade [5,27,28]. The tumor size >5  cm is strongly associated 
with poor prognosis [3,5,9,28,33], as well as the presence of 
distant metastasis at diagnosis and FNCLCC grade 3 [3,27,28]. 
Changchien et al. [23] reported that tumors overexpressing 
EZH2 were also >5 cm in diameter and had distant metasta-
ses, suggesting that EZH2 overexpression is associated with 
greater tumor size, presence of distant metastasis, and poor 
prognosis [23]. We also found a significant correlation between 
high EZH2 expression and tumor size >5 cm (p = 0.014), and 
the presence of distant metastasis (p = 0.018).
Tumor necrosis and high mitotic counts (>10 mitosis/10 
HPFs) have been reported as indicators of a poor prognosis 
in SS [5,9,27]. We found no significant relationship between 
EZH2 expression and mitosis, but there was a significant cor-
relation between high EZH2 expression and the presence of 
necrosis (p = 0.016).
CONCLUSION
Our findings suggest that patients with the tumor size 
≤5 cm, without necrosis, without distant metastasis, and with 
low EZH2 expression had a significantly longer survival time. 
In addition, patients with distant metastasis had a 3.59 risk fac-
tor for the total survival time. Furthermore, we demonstrated 
a significant correlation between high EZH2 expression and 
tumor size >5 cm, necrosis, and distant metastasis. This is con-
sistent with the previous studies suggesting that EZH2 overex-
pression is an indicator of poor prognosis in SS. Our findings 
warrant the confirmation by future studies with larger cohorts 
to determine whether EZH2 expression is an indicator of 
prognosis in SS.
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